Abstract:Drug administration law of the People's Republic of China(2019 revised edition), which came into effect on December 1, 2019, proposed that " the state shall establish a pharmacovigilance system". Pharmacovigilance work of Chinese patent medicines is more difficult, and it is necessary to carry out Pharmacovigilance activities that are in line with the characteristics of Chinese patent medicines. Pharmacovigilance guidelines of Chinese patent medicines(T/CACM 1563. 1-2024), based on the principles of Drug Administration Law of the People's Republic of China(2019 revised edition) and Pharmacovigilance quality management standards(No. 65 of 2021) of the National Medical Products Administration, draws on the EU Pharmacovigilance regulation and the secondary guidelines of International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use(ICH), and it is drafted in accordance with the provisions of Guidelines for standardization work part 1: structure and drafting rules of standardization documents(GB/T1. 1-2020) based on the characteristics of Chinese patent medicines. It serves as a general document for a series of pharmacovigilance guidelines of Chinese patent medicines, such as Guidelines for construction of traditional Chinese medicine pharmacovigilance system in medical institutions(T/CACM 1563. 2-2024), Pharmacovigilance guidelines for clinical application of oral Chinese patent medicines(T/CACM 1563. 3-2024), Pharmacovigilance guidelines for clinical application of traditional Chinese medicine injections(T/CACM 1563. 4-2024), Pharmacovigilance guidelines for clinical application of Chinese patent medicines for external use(T/CACM 1563. 5-2024), and Pharmacovigilance guidelines for clinical application of Chinese patent medicines for mucosal administration(T/CACM 1563. 6-2024), including four major elements of pharmacovigilance monitoring and reporting of Chinese patent medicines, signal identification, risk evaluation, and risk control, as well as pharmacovigilance activities for Chinese patent medicines, ensuring the safety of public drug use.

Discussion on the Applicable Conditions of Article 81 of Regulations for the Implementation of Drug Administration Law

Comparison on Definitions of Counterfeit or Substandard Drugs in Several Countries throughout the World

Evaluation on administration off-label drug use at home and abroad

Analysis of Outpatient Chinese Traditional Patent Medicine Prescriptions During the Third Quarter of 2008 in Our Hospital

On the Amendments of China’s Provisions for Drug Registration

Macroscopic reflections on China’s drug supervision system in transition

Analysis of the problems of drug sampling and testing programme under tripartite system reform in China

Structure and Application of the Exception Principle to Drug Patent Experiments in China

Status Analysis on the Marketing Authorization Holder of China's Drugs

Analysis of the "regulation of Drug Price Difference (trial Implementation)" in China

[Research on evaluation criteria over quality as core index of high grade Chinese patent medicine]

Study on Enterprise Strategies for the Evaluation of Quality and Efficacy Consistency of Generic Drugs

Investigation and analysis of the off-label indications in our hospital

[Pharmacovigilance guidelines of Chinese patent medicines]

Consideration of Legislation of Current Drug Administration Law

Research of Present Domestic Situation on Off-patent Originals and Generics

Analyses on the effects of prescription review of key monitored drugs in one district of Shanghai

Exploration and Practice of the Examination and Management Mode of Adjuvant Drugs in Xiangya Hospital of Central South University

Solving Patent Problem in the Registration and Approval of Drugs

Which Inspection Approach Is Better to Prevent Drug Fraud: Announced or Unannounced?

Overview on the Amendments of Provisions for Drug Registration in China